Anti-Human CD44 (Clone E1/2) - DyLight 650

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Mouse

Immunogen

Purified Recombinant Human CD44 (> 98%)

Product Concentration

0.2 mg/ml

Formulation

This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Handling

This DyLight^® 650 conjugate is stable when stored at 2-8°C. Do not freeze.

Country of Origin

USA

Shipping

Next Day 2-8°C

Excitation Laser

Red Laser (652 nm)

RRID

AB_2828868

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for this E1/2 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone E1/2 recognizes human CD44.

Antigen Distribution

CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.

Background

The CD44 antigen is the cellular receptor for hyaluronic acid. Anti-Human CD44 may be used to study cellular homing and adhesion. This antibody may also be used in studies of T-lymphocyte CD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency. activation.

Antigen Details

Protein

CD44

Ligand/Receptor

Hyaluronan, MIP-1β, fibronectin, collagen

PubMed

CD44

NCBI Gene Bank ID

960

UniProt.org

Information on Uniprot.org

Research Area

Cell Adhesion

.

Cell Biology

.

Immunology

.

Stem Cell

References & Citations

1. Isacke, M.C. et al. (1986) Immunogenetics 23:326

Technical Protocols